Principals of neovascularization for tissue engineering

Masashi Nomi, Anthony Atala, Paolo De Coppi, Shay Soker

Research output: Contribution to journalArticle

292 Citations (Scopus)

Abstract

The goals in tissue engineering include the replacement of damaged, injured or missing body tissues with biological compatible substitutes such as bioengineered tissues. However, due to an initial mass loss after implantation, improved vascularization of the regenerated tissue is essential. Recent advances in understanding the process of blood vessel growth has offered significant tools for therapeutic neovascularization. Several angiogenic growth factors including vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor (bFGF) were used for vascularization of ischemic tissues. Three approaches have been used for vascularization of bioengineered tissue: incorporation of angiogenic factors in the bioengineered tissue, seeding endothelial cells with other cell types and prevascularization of matrices prior to cell seeding. This paper reviews the process of blood vessel growth and tissue vascularization, and discuss strategies for efficient vascularization of engineered tissues.

Original languageEnglish
Pages (from-to)463-483
Number of pages21
JournalMolecular Aspects of Medicine
Volume23
Issue number6
DOIs
StatePublished - Dec 1 2002
Externally publishedYes

Fingerprint

Tissue Engineering
Tissue engineering
Tissue
Angiogenesis Inducing Agents
Endothelial cells
Blood vessels
Blood Vessels
Cell growth
Fibroblast Growth Factor 2
Growth
Vascular Endothelial Growth Factor A
Intercellular Signaling Peptides and Proteins
Endothelial Cells

Keywords

  • Angiogenesis
  • bFGF
  • Endothelial cells
  • Gene therapy
  • VEGF

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Molecular Medicine

Cite this

Principals of neovascularization for tissue engineering. / Nomi, Masashi; Atala, Anthony; De Coppi, Paolo; Soker, Shay.

In: Molecular Aspects of Medicine, Vol. 23, No. 6, 01.12.2002, p. 463-483.

Research output: Contribution to journalArticle

Nomi, Masashi ; Atala, Anthony ; De Coppi, Paolo ; Soker, Shay. / Principals of neovascularization for tissue engineering. In: Molecular Aspects of Medicine. 2002 ; Vol. 23, No. 6. pp. 463-483.
@article{26eed00cf7d14777b835a69e62e3b2ec,
title = "Principals of neovascularization for tissue engineering",
abstract = "The goals in tissue engineering include the replacement of damaged, injured or missing body tissues with biological compatible substitutes such as bioengineered tissues. However, due to an initial mass loss after implantation, improved vascularization of the regenerated tissue is essential. Recent advances in understanding the process of blood vessel growth has offered significant tools for therapeutic neovascularization. Several angiogenic growth factors including vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor (bFGF) were used for vascularization of ischemic tissues. Three approaches have been used for vascularization of bioengineered tissue: incorporation of angiogenic factors in the bioengineered tissue, seeding endothelial cells with other cell types and prevascularization of matrices prior to cell seeding. This paper reviews the process of blood vessel growth and tissue vascularization, and discuss strategies for efficient vascularization of engineered tissues.",
keywords = "Angiogenesis, bFGF, Endothelial cells, Gene therapy, VEGF",
author = "Masashi Nomi and Anthony Atala and {De Coppi}, Paolo and Shay Soker",
year = "2002",
month = "12",
day = "1",
doi = "10.1016/S0098-2997(02)00008-0",
language = "English",
volume = "23",
pages = "463--483",
journal = "Molecular Aspects of Medicine",
issn = "0098-2997",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Principals of neovascularization for tissue engineering

AU - Nomi, Masashi

AU - Atala, Anthony

AU - De Coppi, Paolo

AU - Soker, Shay

PY - 2002/12/1

Y1 - 2002/12/1

N2 - The goals in tissue engineering include the replacement of damaged, injured or missing body tissues with biological compatible substitutes such as bioengineered tissues. However, due to an initial mass loss after implantation, improved vascularization of the regenerated tissue is essential. Recent advances in understanding the process of blood vessel growth has offered significant tools for therapeutic neovascularization. Several angiogenic growth factors including vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor (bFGF) were used for vascularization of ischemic tissues. Three approaches have been used for vascularization of bioengineered tissue: incorporation of angiogenic factors in the bioengineered tissue, seeding endothelial cells with other cell types and prevascularization of matrices prior to cell seeding. This paper reviews the process of blood vessel growth and tissue vascularization, and discuss strategies for efficient vascularization of engineered tissues.

AB - The goals in tissue engineering include the replacement of damaged, injured or missing body tissues with biological compatible substitutes such as bioengineered tissues. However, due to an initial mass loss after implantation, improved vascularization of the regenerated tissue is essential. Recent advances in understanding the process of blood vessel growth has offered significant tools for therapeutic neovascularization. Several angiogenic growth factors including vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor (bFGF) were used for vascularization of ischemic tissues. Three approaches have been used for vascularization of bioengineered tissue: incorporation of angiogenic factors in the bioengineered tissue, seeding endothelial cells with other cell types and prevascularization of matrices prior to cell seeding. This paper reviews the process of blood vessel growth and tissue vascularization, and discuss strategies for efficient vascularization of engineered tissues.

KW - Angiogenesis

KW - bFGF

KW - Endothelial cells

KW - Gene therapy

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=0036883670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036883670&partnerID=8YFLogxK

U2 - 10.1016/S0098-2997(02)00008-0

DO - 10.1016/S0098-2997(02)00008-0

M3 - Article

VL - 23

SP - 463

EP - 483

JO - Molecular Aspects of Medicine

JF - Molecular Aspects of Medicine

SN - 0098-2997

IS - 6

ER -